Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study
Background: In the latter half of 2023, the northern hemisphere initiated the rollout of nirsevimab immunization strategies for infants, yielding promising early results. As Chile prepared for its 2024 strategy implementation, we retrospectively evaluated the potential cost-saving nature of various...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Journal of Infection and Public Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034125000292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087781273239552 |
|---|---|
| author | Denis Sauré Miguel O’Ryan Juan Pablo Torres Natalia Trigo Gonzalo Diaz Marcel Goic Charles Thraves Jorge Pacheco Patricio Aguilera Andrea Caro Leonardo J. Basso |
| author_facet | Denis Sauré Miguel O’Ryan Juan Pablo Torres Natalia Trigo Gonzalo Diaz Marcel Goic Charles Thraves Jorge Pacheco Patricio Aguilera Andrea Caro Leonardo J. Basso |
| author_sort | Denis Sauré |
| collection | DOAJ |
| description | Background: In the latter half of 2023, the northern hemisphere initiated the rollout of nirsevimab immunization strategies for infants, yielding promising early results. As Chile prepared for its 2024 strategy implementation, we retrospectively evaluated the potential cost-saving nature of various immunization strategies. Methods: Leveraging comprehensive inpatient, outpatient, and sentinel programs data, we conduct a simulation-based retrospective analysis to evaluate the net cost savings of various immunization strategies based on nirsevimab. We first characterize RSV burden among Chilean infants between 2019 and 2023, focusing on medically attended lower respiratory tract infections (MA LRTI), hospital admissions (HA LRTI), and severe cases requiring ICU admission (ICU LRTI). Utilizing nirsevimab efficacy estimates, we simulate counterfactual scenarios to estimate reductions in outpatient visits, hospitalizations, and ICU admissions had nirsevimab been used. We evaluate diverse immunization strategies and estimate their cost-saving status. Findings: With nirsevimab costing about USD$225 per dose, immunizing infants under 6 months before the RSV season, all newborns during the season, and high-risk groups would have been cost-saving in 2023 and 2019. This strategy would have significantly decreased the strain on the healthcare system during the seasonal surge, reducing 13,533 ICU (77·81/1000 live newborns) and 27,465 hospital bed requirements (157·91/1000 live newborns), alongside 46,886 emergency room visits (269·58/1000 live newborns). Interpretation: In Chile, a country with a GDP per capita of USD$17,000, various immunization strategies are cost-saving for scenarios comparable to pre-pandemic 2019 and to the particularly severe 2023 when considering only those direct costs associated with patient care, albeit differing in their impact in health outcomes. The resulting decrease in healthcare strain during the Winter virus surge underscores the strategy’s impact. |
| format | Article |
| id | doaj-art-942b8bb2b0ae4a1a8895547442dd40a1 |
| institution | Kabale University |
| issn | 1876-0341 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Infection and Public Health |
| spelling | doaj-art-942b8bb2b0ae4a1a8895547442dd40a12025-02-06T05:11:27ZengElsevierJournal of Infection and Public Health1876-03412025-04-01184102680Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective studyDenis Sauré0Miguel O’Ryan1Juan Pablo Torres2Natalia Trigo3Gonzalo Diaz4Marcel Goic5Charles Thraves6Jorge Pacheco7Patricio Aguilera8Andrea Caro9Leonardo J. Basso10Industrial Engineering Department, Universidad de Chile, and Instituto Sistemas Complejos de Ingeniería (ISCI), Av. Beauchef 851, Santiago 8370456, ChilePrograma de Microbiología y Micología in the Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile and Instituto Sistemas Complejos de Ingeniería (ISCI), ChileDepartment of Pediatrics and Pediatric Surgery, Facultad de Medicina, Universidad de Chile, and Instituto Sistemas Complejos de Ingeniería (ISCI), ChileInstituto Sistemas Complejos de Ingeniería (ISCI), ChileInstituto Sistemas Complejos de Ingeniería (ISCI), ChileIndustrial Engineering Department, Universidad de Chile, and Instituto Sistemas Complejos de Ingeniería (ISCI), Av. Beauchef 851, Santiago 8370456, ChileIndustrial Engineering Department, Universidad de Chile, and Instituto Sistemas Complejos de Ingeniería (ISCI), Av. Beauchef 851, Santiago 8370456, ChileDepartamento de Estadísticas e Información de Salud, Ministerio de Salud de Chile, ChileDepartamento de Estadísticas e Información de Salud, Ministerio de Salud de Chile, ChileDepartamento de Eficiencia Hospitalaria, Ministerio de Salud de Chile, ChileIndustrial Engineering Department, Universidad de Chile, and Instituto Sistemas Complejos de Ingeniería (ISCI), Av. Beauchef 851, Santiago 8370456, Chile; Corresponding author.Background: In the latter half of 2023, the northern hemisphere initiated the rollout of nirsevimab immunization strategies for infants, yielding promising early results. As Chile prepared for its 2024 strategy implementation, we retrospectively evaluated the potential cost-saving nature of various immunization strategies. Methods: Leveraging comprehensive inpatient, outpatient, and sentinel programs data, we conduct a simulation-based retrospective analysis to evaluate the net cost savings of various immunization strategies based on nirsevimab. We first characterize RSV burden among Chilean infants between 2019 and 2023, focusing on medically attended lower respiratory tract infections (MA LRTI), hospital admissions (HA LRTI), and severe cases requiring ICU admission (ICU LRTI). Utilizing nirsevimab efficacy estimates, we simulate counterfactual scenarios to estimate reductions in outpatient visits, hospitalizations, and ICU admissions had nirsevimab been used. We evaluate diverse immunization strategies and estimate their cost-saving status. Findings: With nirsevimab costing about USD$225 per dose, immunizing infants under 6 months before the RSV season, all newborns during the season, and high-risk groups would have been cost-saving in 2023 and 2019. This strategy would have significantly decreased the strain on the healthcare system during the seasonal surge, reducing 13,533 ICU (77·81/1000 live newborns) and 27,465 hospital bed requirements (157·91/1000 live newborns), alongside 46,886 emergency room visits (269·58/1000 live newborns). Interpretation: In Chile, a country with a GDP per capita of USD$17,000, various immunization strategies are cost-saving for scenarios comparable to pre-pandemic 2019 and to the particularly severe 2023 when considering only those direct costs associated with patient care, albeit differing in their impact in health outcomes. The resulting decrease in healthcare strain during the Winter virus surge underscores the strategy’s impact.http://www.sciencedirect.com/science/article/pii/S1876034125000292Respiratory syncytial virusNirsevimabCost-savingMonoclonal antibodiesCosteffectiveness |
| spellingShingle | Denis Sauré Miguel O’Ryan Juan Pablo Torres Natalia Trigo Gonzalo Diaz Marcel Goic Charles Thraves Jorge Pacheco Patricio Aguilera Andrea Caro Leonardo J. Basso Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study Journal of Infection and Public Health Respiratory syncytial virus Nirsevimab Cost-saving Monoclonal antibodies Costeffectiveness |
| title | Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study |
| title_full | Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study |
| title_fullStr | Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study |
| title_full_unstemmed | Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study |
| title_short | Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study |
| title_sort | cost savings and health impact of strategies for prevention of respiratory syncytial virus with nirsevimab in chile based on the integrated analysis of 2019 2023 national databases a retrospective study |
| topic | Respiratory syncytial virus Nirsevimab Cost-saving Monoclonal antibodies Costeffectiveness |
| url | http://www.sciencedirect.com/science/article/pii/S1876034125000292 |
| work_keys_str_mv | AT denissaure costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT migueloryan costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT juanpablotorres costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT nataliatrigo costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT gonzalodiaz costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT marcelgoic costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT charlesthraves costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT jorgepacheco costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT patricioaguilera costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT andreacaro costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy AT leonardojbasso costsavingsandhealthimpactofstrategiesforpreventionofrespiratorysyncytialviruswithnirsevimabinchilebasedontheintegratedanalysisof20192023nationaldatabasesaretrospectivestudy |